Magnetic resonance imaging contrast-enhanced relaxometry of breast tumors: an MRI multicenter investigation concerning 100 patients.

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using extracellular contrast agents has proved to be useful for the characterization of breast tumors. DCE-MRI has demonstrated a high sensitivity (around 95%) but a rather poor and controversial specificity, varying, according to the different studies, from 45% to 90%. In order to increase (a) the specificity and (b) the robustness of this quantitative approach in multicenter evaluation (five MRI units), a quantitative approach called dynamic relaxometry has been developed. According to the proposed method, the time-dependent longitudinal relaxation rate measured on region of interest of the lesion was calculated during the contrast uptake, after intravenous bolus injection of contrast agent. A specifically developed method was used for fast R(1) measurements. Relaxometry time curves are fitted to the Tofts model allowing the measurement of the parameters describing the enhancement curve (maximum relation rate enhancement, initial, 30-s and 60-s slopes) and the tissue parameters [transfer constant (K(trans) min(-1)) and extracellular extravascular space fraction (v(e))]. Correspondence factorial analysis followed by hierarchical ascendant classification are then performed on the different parameters. Higher K(trans) values were observed in infiltrative ductal carcinomas than in infiltrative lobular carcinomas, in agreement with data published by other groups. Specificity of DCE-MRI has been increased up to 85%, with a sensitivity of 95% with K(trans)/v(e) and enhancement index I (ratio of initial slope by maximum relaxation rate enhancement). A multiparametric data analysis of the calculated parameters opens the way to include quantitative image-based information in new nosologic approaches to breast tumors.

[1]  G. Newstead,et al.  MR imaging of the breast. , 1995, Radiology.

[2]  H Lyng,et al.  MRI of human tumor xenografts in vivo: proton relaxation times and extracellular tumor volume. , 1995, Magnetic resonance imaging.

[3]  U. Fischer,et al.  International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions , 2001, European Radiology.

[4]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W. Kaiser,et al.  MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. , 1989, Radiology.

[6]  T W Redpath,et al.  Measurement of spin-lattice relaxation times with FLASH for dynamic MRI of the breast. , 1996, The British journal of radiology.

[7]  J. Renou,et al.  Measurements of extracellular volume fraction and capillary permeability in tissues using dynamic spin-lattice relaxometry: studies in rabbit muscles. , 2003, Magnetic resonance imaging.

[8]  F. Kelcz,et al.  Critical role of spatial resolution in dynamic contrast‐enhanced breast MRI , 2001, Journal of magnetic resonance imaging : JMRI.

[9]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Scott Fields,et al.  Mapping pathophysiological features of breast tumors by MRI at high spatial resolution , 1997, Nature Medicine.

[11]  M. Leach,et al.  Breast imaging technology: Imaging biochemistry - applications to breast cancer , 2000, Breast Cancer Research.

[12]  Edison T Liu,et al.  Classification of cancers by expression profiling. , 2003, Current opinion in genetics & development.

[13]  J. D. de Certaines,et al.  Performance assessment and quality control in MRI by Eurospin test objects and protocols. , 1993, Magnetic resonance imaging.

[14]  G J Parker,et al.  Accurate multislice gradient echo T1 measurement in the presence of non‐ideal RF pulse shape and RF field nonuniformity , 2001, Magnetic resonance in medicine.

[15]  A Heinig,et al.  Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. , 1997, European journal of radiology.

[16]  G Brix,et al.  Multicompartment analysis of gadolinium chelate kinetics: Blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.

[17]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[18]  S. Heywang-Köbrunner,et al.  Contrast-Enhanced MRI of the Breast , 1991 .

[19]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[20]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[21]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[22]  A. Haase,et al.  Snapshot flash mri. applications to t1, t2, and chemical‐shift imaging , 1990, Magnetic resonance in medicine.

[23]  R. Edelman,et al.  Magnetic resonance imaging (2) , 1993, The New England journal of medicine.

[24]  B K Rutt,et al.  Temporal sampling requirements for the tracer kinetics modeling of breast disease. , 1998, Magnetic resonance imaging.

[25]  S. Heywang,et al.  MR imaging of the breast with Gd-DTPA: use and limitations. , 1989, Radiology.

[26]  J. Renou,et al.  In vivo tissue extracellular volume fraction measurement by dynamic spin-lattice MRI relaxometry: application to the characterization of muscle fiber types. , 1999, Investigative radiology.

[27]  A. Padhani Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.

[28]  G J Parker,et al.  Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. , 1999, Topics in magnetic resonance imaging : TMRI.

[29]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[30]  Heywang-Köbrunner Sh,et al.  Contrast-enhanced magnetic resonance imaging of the breast. , 1994, Investigative radiology.

[31]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.